{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:06:25Z","timestamp":1788051985646,"version":"build-2784847793"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Evocalcet is a novel calcimimetic agent for the treatment of secondary hyperparathyroidism (<jats:styled-content style=\"fixed-case\">SHPT<\/jats:styled-content>). This study evaluated the effects of evocalcet on inhibition and induction of cytochrome P450 (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>) isozymes. Although drug interactions arising from reversible inhibition of <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content> isozymes by evocalcet were considered unlikely based on the results of <jats:italic>in vitro<\/jats:italic> studies and static model analyses, the potential for evocalcet to cause time\u2010dependent inhibition of <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A or induction of several <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content> isozymes could not be ruled out. Therefore, a clinical drug\u2010drug interaction (DDI) study to evaluate the effects of evocalcet on the pharmacokinetics (PKs) of probe substrates for <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content> isozymes (<jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>1A2, <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2B6, <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C8, <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>2C9, and <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>3A) was conducted in healthy male volunteers using a novel cocktail combination. Evocalcet did not significantly affect the PKs of the probe substrates, confirming that <jats:styled-content style=\"fixed-case\">CYP<\/jats:styled-content>\u2010mediated interactions were unlikely.<\/jats:p>","DOI":"10.1111\/cts.12588","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T22:27:12Z","timestamp":1537568832000},"page":"20-27","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Assessment of <scp>CYP<\/scp>\u2010Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on <i>In Vitro<\/i> Investigations and a Cocktail Study in Humans"],"prefix":"10.1111","volume":"12","author":[{"given":"Kazuya","family":"Narushima","sequence":"first","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanari","family":"Shiramoto","sequence":"additional","affiliation":[{"name":"SOUSEIKAI Hakata Clinic  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Endo","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Nagata","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Uchimura","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kannami","sequence":"additional","affiliation":[{"name":"DMPK Research Laboratories Innovative Research Division Mitsubishi Tanabe Pharma Corporation  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[{"name":"R&amp;D Division Kyowa Hakko Kirin Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Metabolism Department of Internal Medicine Tokai University School of Medicine  Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology Department of Medicine Showa University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.020"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12030"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01781-8"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.279"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057273"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-006-0687-y"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.019"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm534"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07050714"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11501210"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.13081211"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2013.91"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12352"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001436"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2009.00397.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746060-00003"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007304103"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195316"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.05.013"},{"key":"e_1_2_10_22_1","unstructured":"Food and Drug Administration.Draft Guidance\/Guidance for Industry. In vitro metabolism\u2010 and transporter\u2010mediated drug\u2010drug interaction studies.<https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM581965.pdf> (2017). Accessed April 25 2018."},{"key":"e_1_2_10_23_1","unstructured":"Food and Drug Administration.Draft Guidance\/Guidance for Industry. Clinical drug interaction studies \u2010 study design data analysis and clinical implications<https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf> (2017). Accessed April 25 2018."},{"key":"e_1_2_10_24_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions<http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf> (2012). Accessed April 25 2018."},{"key":"e_1_2_10_25_1","unstructured":"Ministry of Health Labour and Welfare Japan.Guideline of drug interaction studies for drug development and appropriate provision of information<https:\/\/www.pmda.go.jp\/files\/000206158.pdf>(2014). Accessed April 25 2018."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.012633"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0930.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032798678907900"},{"key":"e_1_2_10_29_1","first-page":"283","article-title":"Human hepatocyte culture","volume":"320","author":"Pichard L.","year":"2006","journal-title":"Methods Mol. Biol."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.187"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100054"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250902846252"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240407"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.109519"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01973.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100187"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1603-8"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13097"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0497-0"},{"key":"e_1_2_10_41_1","unstructured":"Efavirenz [package insert]. Morgantown WV: Mylan Pharmaceuticals Inc. (2015)."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920009789375397"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:38:39Z","timestamp":1694720319000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1111\/cts.12588"],"URL":"https:\/\/doi.org\/10.1111\/cts.12588","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"2018-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}